Submental Fat Clinical Trial
Official title:
A Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled Study of the Safety and Efficacy of 10XB-101 in Adult Subjects With Submental Fat
The purpose of this research study is to determine the safety and efficacy of 10XB-101 vs. vehicle (placebo) for adults with excessive submental fat (SMF).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05476679 -
Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
|
Phase 1/Phase 2 | |
Completed |
NCT04144049 -
A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
|
Phase 2 | |
Completed |
NCT04258761 -
A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin")
|
Phase 2 | |
Completed |
NCT05763160 -
An Open-label Study That Will Test a Second Treatment Session of RZL-012.
|
Phase 2 | |
Completed |
NCT03946592 -
Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat
|
Phase 3 | |
Completed |
NCT04867434 -
Efficacy and Safety of RZL-012 on Submental Fat Reduction
|
Phase 2 | |
Completed |
NCT05466448 -
An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.
|
Phase 1/Phase 2 | |
Completed |
NCT04086823 -
A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.
|
Phase 2 | |
Completed |
NCT02159729 -
Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
|
Phase 2 | |
Completed |
NCT05195112 -
Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
|
Phase 3 | |
Completed |
NCT03005717 -
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat
|
Phase 2 | |
Completed |
NCT02163902 -
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
|
Phase 3 | |
Completed |
NCT05476094 -
Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects
|
Phase 1 |